Genetic-guided Risk Assessment and Management of Thyroid Cancer

Research output: Contribution to journalReview article

Abstract

Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.

Original languageEnglish (US)
Pages (from-to)109-124
Number of pages16
JournalEndocrinology and metabolism clinics of North America
Volume48
Issue number1
DOIs
StatePublished - Mar 2019

Keywords

  • BRAF V600E mutation
  • Genetic molecular marker
  • Prognosis
  • RAS mutation
  • Risk stratification
  • TERT promoter Mutation
  • Thyroid cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Genetic-guided Risk Assessment and Management of Thyroid Cancer'. Together they form a unique fingerprint.

  • Cite this